Founded in Los Angeles, NeuroSigma, Inc. is a life science company dedicated to developing bioelectronic products aimed at treating neurological and neuropsychiatric disorders. Their core mission is to provide innovative, non-invasive treatment options for conditions like epilepsy, depression, and pediatric ADHD. The company's flagship product, the Monarch eTNS® System, is the first FDA-cleared device for treating pediatric ADHD in children aged 7 to 12 who are not on prescription medications. This device is designed for home use under caregiver supervision.
NeuroSigma has garnered attention and support from notable investors and experts in the medical field. The company's key achievements include the FDA clearance of the Monarch eTNS System, marking a significant milestone in non-pharmacological treatment options for ADHD. The overall impact of NeuroSigma's innovations lies in offering new hope and improved quality of life for patients with challenging neurological and neuropsychiatric conditions.
